Paul Bycott

9.0k citations
51 papers · 7.1k · 2 hit papers · h-index 24

Impact in

Papers in

Paul Bycott

50 papers receiving 6.9k citations

Paul Bycott's Hit Papers

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study 2008 · 494 citations
4940+6+12Years since publication10002.0k3.0k4.0k

Peers

Paul Bycott
Comparison fields: 5 of 118
  • Cancer Research 2.2k
  • Pulmonary and Respiratory Medicine 4.5k
  • Oncology 2.9k
  • Molecular Biology 3.7k
  • Endocrinology, Diabetes and Metabolism 518
Replace Isan Chen with:
Isan Chen United States
David Olmos United Kingdom
Hidefumi Sasaki Japan
Tomasz Demkow Poland
Christine Théodore France
Frédéric Rolland France
Wanling Xie United States
Apurva A. Desai United States
Daniel Castellano Spain
Sergio Bracarda Italy
Paul Bycott relative to Isan Chen United States Isan Chen's profile →
Citations per field
00.5×1.5×2.1×
Isan Chen · 1×
Citations per year

Countries citing papers authored by Paul Bycott

Since Specialization
Citations

This map shows the geographic impact of Paul Bycott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Bycott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Bycott more than expected).

Fields of papers citing papers by Paul Bycott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Bycott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Bycott. The network helps show where Paul Bycott may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul Bycott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Bycott Line = papers co-authored together Paul Bycott links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Hit paper breakdown →
20074471
2
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Hit paper breakdown →
2008494
3 2007356
4 2011322
5 2008204
6 2009146
7 2003106
8 201486
9 201184
10 200571
11 199862
12 200762
13 201447
14 200844
15 201442
16 201139
17 200538
18 201336
19 200735
20 202133

About Paul Bycott

Paul Bycott is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Economics and Econometrics, having authored 51 papers that have together received 7.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (19 papers), Cancer Genomics and Diagnostics (17 papers), Lung Cancer Treatments and Mutations (11 papers), Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Economic and Financial Impacts of Cancer (7 papers), Renal and related cancers (6 papers) and Statistical Methods in Clinical Trials (6 papers). The work is most often cited by research in Cancer Research (2.2k citations), Pulmonary and Respiratory Medicine (4.5k citations), Oncology (2.9k citations), Molecular Biology (3.7k citations) and Endocrinology, Diabetes and Metabolism (518 citations). Paul Bycott has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Olivier Rixe, M. Dror Michaelson, Robert J. Motzer, Ronald M. Bukowski, Thomas E. Hutson, Sylvie Négrier, Piotr Tomczak, Stéphane Oudard, Robert A. Figlin and Cezary Szczylik. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, BMC Cancer, The Lancet Oncology and Statistics in Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact